Approved & therapeutic
Lutropin alfa
Luveris
Lutropin alfa is recombinant human luteinising hormone, approved for use with follitropin alfa to stimulate follicular development in women with profound LH deficiency.
Also known as: r-hLH, recombinant LH
- Status
- Lutropin alfa is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 10 to 12 hours after subcutaneous administration.
- How it's taken
- Subcutaneous injection, given with follitropin alfa
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- Estrogen, Androgen
How Lutropin alfa works
LH acts on ovarian theca cells to produce androgen precursors, which granulosa cells then aromatise to estradiol under FSH stimulation. Women with hypogonadotropic hypogonadism lack sufficient LH for this two-cell process, so FSH alone produces follicles without adequate estradiol. Lutropin alfa supplies the missing LH activity.
What research has looked at
- Restores the LH component of the two-cell, two-gonadotropin model in women with profound LH deficiency, where FSH alone is insufficient.
- Recombinant production gives a defined, consistent LH activity without the FSH contamination of urinary preparations.
- It addresses a narrow but genuine population — profound hypogonadotropic hypogonadism — rather than being a general adjunct to stimulation.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Ovarian hyperstimulation syndrome when combined with FSH stimulation.
- Multiple pregnancy.
- Injection-site reactions, headache, nausea and breast pain.
- It has no established benefit in normogonadotropic women, and adding LH activity routinely is not supported.
- Ovarian enlargement and torsion.
Sources
- FDA approved-drug listing for lutropin alfa · U.S. Food & Drug Administration
- DailyMed prescribing information for lutropin alfa · NIH · DailyMed
- PubMed research on recombinant LH hypogonadotropic hypogonadism · NIH · National Library of Medicine
- DrugBank record for lutropin alfa · DrugBank
Track Lutropin alfa in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Lutropin alfa FAQ
What is Lutropin alfa?
Lutropin alfa is recombinant human luteinising hormone, approved for use with follitropin alfa to stimulate follicular development in women with profound LH deficiency.
How does Lutropin alfa work?
LH acts on ovarian theca cells to produce androgen precursors, which granulosa cells then aromatise to estradiol under FSH stimulation. Women with hypogonadotropic hypogonadism lack sufficient LH for this two-cell process, so FSH alone produces follicles without adequate estradiol. Lutropin alfa supplies the missing LH activity.
Is Lutropin alfa FDA approved?
Yes. Lutropin alfa is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Lutropin alfa?
Reported half-life: Approximately 10 to 12 hours after subcutaneous administration.
How is Lutropin alfa taken?
Subcutaneous injection, given with follitropin alfa.
What side effects have been reported with Lutropin alfa?
Reported in the sources: Ovarian hyperstimulation syndrome when combined with FSH stimulation; Multiple pregnancy; Injection-site reactions, headache, nausea and breast pain; It has no established benefit in normogonadotropic women, and adding LH activity routinely is not supported; Ovarian enlargement and torsion.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.